Director, Master of Science in Infectious Disease and Global Health
Associate Professor Abhineet Sheoran, DVM, PhD, is an immunologist and infectious disease specialist with >15 years of experience on immunology, immunotherapy of toxin-mediated diseases, animal models, and development of vaccines for mucosal pathogens. He jointly runs a program to develop a therapy for hemolytic uremic syndrome (HUS) and a vaccine for cryptosporidiosis with Professor Saul Tzipori. He teaches in several courses in the DVM and graduate programs and directs a course on immunology. He is the director of the twelve-month Master of Science in Infectious Disease and Global Health degree program.
Dr. Sheoran’s laboratory is engaged in preclinical evaluations of antitoxin agents against Shiga toxin 1 (Stx1) and Stx2 of enterohemorrhagic E. coli (EHEC) in animal models. Stx1 and Stx2 are associated with HUS following infection with EHEC that people contract by eating contaminated vegetables or undercooked meat.
Another project in Dr. Sheoran’s laboratory is to develop a vaccine for cryptosporidiosis, an infection caused by the enteric pathogens Cryptosporidium parvum and C. hominis. Cryptosporidiosis is a globally important zoonotic disease, which is second only to rotavirus as a cause of diarrhea in children < 2 years of age in sub-Saharan Africa and South Asia. Cryptosporidium also causes sporadic diarrheal illness in industrialized countries, including the US. Currently, there is no effective therapy or vaccine against this disease.
Before coming to Tufts, Dr. Sheoran did his doctoral work on equine humoral immunity at the University of Cambridge, England, and pursued his interests in the same field during post-doctoral training at the University of Kentucky, where he worked on developing mucosal vaccines and investigating virulence factors of equine microbial pathogens.
PhD, University of Cambridge, England, 1996
MVSc, Haryana Agricultural University, India, 1991
DVM, Haryana Agricultural University, India, 1989
Immunology and pathogenesis of human/zoonotic infectious agents.
Immunotherapy for hemolytic uremic syndrome (HUS) that can develop following infection with Shiga toxin-producing E. coli.
Vaccine development for cryptosporidiosis and leptospirosis.
Selected Research Projects
Development of strategies to achieve immunoprotection against C. hominis and C. parvum: We are undertaking a series of studies in the piglet model to address the fundamental hypothesis that specific antibodies can protect against Cryptosporidium. We expect to identify a combination of 3-4 antigens that can be used to develop an effective cryptosporidiosis vaccine for protection of infants and children. Read more about Dr. Sheoran’s Research Lab
Development of immunotherapy for hemolytic uremic syndrome (HUS): HUS can develop following infection with Shiga toxin-producing E. coli. This syndrome is the single most important cause of kidney failure in children in the US and other developed countries. We are evaluating antibody- and VHH-based neutralizing agents against Shiga toxins in animal models to develop therapy for HUS. Read more about Dr. Sheoran’s Research Lab
Sheoran AS, Dmitriev IP, Kashentseva EA, Cohen O, Mukherjee J, Debatis M, Shearer J, Tremblay JM, Beamer G, Curiel DT, Shoemaker CB, Tzipori S. 2014. Adenovirus vector expressing Stx1/2-neutralizing agent protects piglets infected with E. coli O157:H7 against fatal systemic intoxication. Infect Immun. Nov, [Epub ahead of print].
Challa S, Tzipori S and Sheoran A. 2014. Selective evolution of ligands by exponential enrichment to identify RNA aptamers against Shiga toxins. Journal of Nucleic Acids. 2014: 1-8.
Tremblay JM, Mukherjee J, Leysath CE, Debatis M, Ofori K, Baldwin K, Boucher C, Peters R, Beamer G, Sheoran A, Bedenice D, Tzipori S, Shoemaker CB. 2013. A single VHH-based toxin-neutralizing agent and an effector antibody protect mice against challenge with Shiga toxins 1 and 2. Infect Immun. 81(12):4592-603
Sheoran A, Jeong KI, Mukherjee J, Wiffin A, Singh P, Tzipori S. 2012. Biodistribution and elimination kinetics of systemic Stx2 by the Stx2A and Stx2B subunit-specific human monoclonal antibodies in mice. BMC Immunol. 13(1):27.
Sheoran A, Wiffin A, Widmer G, Singh P, Tzipori S. 2012. Infection with Cryptosporidium hominis provides incomplete protection of the host against Cryptosporidium parvum. J Infect Dis. 205(6):1019-23.
Challa S, Nally JE, Jones C and Sheoran A. 2011. Passive immunization with Leptospira LPS-specific agglutinating but not non-agglutinating monoclonal antibodies protect guinea pigs from fatal pulmonary hemorrhages induced by serovar Copenhageni challenge. Vaccine. 29(27):4431-4.
Jeong KI, Chapman-Bonofiglio S, Singh P, Lee J, Tzipori S, Sheoran A. 2010. In vitro and in vivo protective efficacies of antibodies that neutralize the RNA N-glycosidase activity of Shiga toxin 2. BMC Immunol. 11(1):16.
Jeong KI, Tzipori S, Sheoran AS. 2010. Shiga toxin 2-specific but not Shiga toxin 1-specific human monoclonal antibody protects piglets challenged with enterohemorrhagic Escherichia coli producing Shiga toxin 1 and Shiga toxin 2. J Infect Dis. 201(7):1081-1083.
Akiyoshi DE, Sheoran AS, Rich CM, Richard L, Chapman-Bonofiglio S, Tzipori S. 2010. Evaluation of Fab and F(ab’)2 fragments and isotype variants of a recombinant human monoclonal antibody against Shiga toxin 2. Infect Immun. 78(3):1376-1382.
Yang YL, Serrano MG, Sheoran AS, Manque PA, Buck GA, Widmer G. 2009. Over-expression and localization of a host protein on the membrane of Cryptosporidium parvum infected epithelial cells. Mol Biochem Parasitol. 168(1):95-101.
Krautz-Peterson G, Chapman-Bonofiglio S, Boisvert K, Feng H, Herman IM, Tzipori S, Sheoran AS. 2008. Intracellular neutralization of Shiga toxin 2 by an A subunit-specific human monoclonal antibody. Infect Immun. 76(5):1931-1939.
Feng H, Nie W, Sheoran A, Zhang Q, Tzipori S. 2006. Bile Acids Enhance Invasiveness of Cryptosporidium spp. into Cultured Cells. Infect Immun. 74:3342-3346.
Sheoran AS, Feng X, Singh I, Chapman-Bonofiglio S, Kitaka S, Hanawalt J, Nunnari J, Mansfield K, Tumwine JK, Tzipori S, 2005. Monoclonal Antibodies against Enterocytozoon bieneusi of human origin. J Clin Diag Lab Immunol. 12: 1109-1113.
Sheoran AS, Chapman-Bonofiglio S, Harvey BR, Mukherjee J, Georgiou G, Donohue-Rolfe A, Tzipori S. 2005. Human antibody against shiga toxin 2 administered to piglets after the onset of diarrhea due to Escherichia coli O157:H7 prevents fatal systemic complications. Infect Immun. 73: 4607-4613.
Sheoran AS, Feng X, Kitaka S, Green L, Pearson C, Didier ES, Chapman S, Tumwine JK, Tzipori S. 2005. Purification of Enterocytozoon bieneusi from stool and production of specific antibodies. J Clin Microbiol. 43: 387-392.
Tzipori S, Sheoran AS, Akiyoshi D, Donohue-Rolfe A, Trachtman H. 2004. Antibody therapy in the management of shiga toxin-induced hemolytic uremic syndrome. Clinical Microbiol Reviews. 17: 926-941.
Sheoran AS, Chapman S, Singh P, Donohue-Rolfe A, Tzipori S. 2003. Stx2-specific human monoclonal antibodies protect mice against lethal infection with Escherichia coli expressing Stx2 variants. Infect Immun. 71:3125-3130.
Sheoran AS, Timoney JF, Tinge SA, Sundaram P, Curtiss III R. 2001. Intranasal immunogenicity of a Dcya Dcrp-pabA mutant of S. typhimuriium for the horse.Vaccine. 19: 3591-3599.
Sheoran AS, Nally JE, Donahue JM, Smith BJ, Timoney JF. 2000. Antibody isotypes in sera of equine fetuses aborted due to Leptospira interrogans serovar pomona-type kennewicki infection. Vet. Immunol. Immunopathol. 77:301-309.
Sheoran AS, Timoney JF, Holmes MA, Karzen, Crisman MV. 2000. Immunoglobulin isotypes in equine sera and nasal mucosal secretions and their neonatal transfer and distribution. Am. J. Vet. Res. 61: 1099-1105.